Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) Book value per share
Sanofi's book value per share at the end of fiscal 2025 was 33.2×, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was 35.1×. Over the past ten years it has ranged from 24.7× (fiscal 2015) to 33.7× (fiscal 2024); the current reading is higher than 91% of that period. Sanofi ranks 3rd of 21 Drug Manufacturers General companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 33.2× | (1.25%) |
| FY2024 | 33.7× | 4.72% |
| FY2023 | 32.1× | 1.65% |
| FY2022 | 31.6× | (3.00%) |
| FY2021 | 32.6× | 13.32% |
| FY2020 | 28.8× | 8.64% |
| FY2019 | 26.5× | (5.26%) |
| FY2018 | 28.0× | 6.71% |
| FY2017 | 26.2× | 5.52% |
| FY2016 | 24.8× | 0.33% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 35.1× | 3.93% |
| Jun 2026 | 33.8× | (4.91%) |
| Mar 2026 | 35.5× | 6.93% |
| Dec 2025 | 33.2× | (5.79%) |
| 39 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| SNY Sanofi | 35.1× |
| AZN AstraZeneca PLC compare | 33.4× |
| AMGN Amgen Inc. compare | 26.5× |
| NVS Novartis AG compare | 19.8× |
| PFE Pfizer Inc. compare | 15.7× |
| GSK GSK PLC Sponsored ADR compare | 12.3× |
| BMY Bristol Myers Squibb Company compare | 11.5× |
| GILD Gilead Sciences, Inc. compare | 10.4× |
| NVO Novo Nordisk A/S compare | 7.8× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement